Physiomics (LSE:PYC) ROCE %: -120.55% (As of Dec. 2025)


What is Physiomics ROCE %?

Physiomics LSE:PYC ROCE % is -120.55% as of Dec. 2025. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Physiomics's annualized ROCE % for the quarter that ended in Dec. 2025 was -120.55%.

Physiomics  (LSE:PYC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Physiomics ROCE % Related Terms

Physiomics ROCE % Historical Data

* Premium members only.

The historical data trend for Physiomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Physiomics ROCE % Chart

Physiomics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.19 -33.57 -76.01 -164.37 -93.74

Physiomics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.47 -181.36 -142.08 -74.95 -120.55

Physiomics ROCE % Calculation

Physiomics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-0.457/( ( (0.423 - 0.14) + (0.892 - 0.2) )/ 2 )
=-0.457/( (0.283+0.692)/ 2 )
=-0.457/0.4875
=-93.74 %

Physiomics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-0.654/( ( (0.892 - 0.2) + (0.558 - 0.165) )/ 2 )
=-0.654/( ( 0.692 + 0.393 )/ 2 )
=-0.654/0.5425
=-120.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -120.55% mean?
Physiomics (LSE:PYC) has a ROCE % of -120.55% as of Dec. 2025.
Is Physiomics' ROCE % too high?
Physiomics' current ROCE % is -120.55%.
How does Physiomics' ROCE % compare to VRTX and REGN?
Physiomics' ROCE % of -120.55% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Physiomics's current ROCE % is -120.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Physiomics stock overvalued right now?
Based on GuruFocus' analysis, Physiomics (LSE:PYC) is currently considered Possible Value Trap. The stock's GF Value™ is £0.01, compared to a current price of £0.00 — trading 52.5% below its estimated fair value. The current ROCE % is -120.55%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Physiomics (LSE:PYC), the current ROCE % is -120.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Physiomics Business Description

Other Exchanges RVW1:Germany
Address 140 Eastern Avenue, Bee House, Milton Park, Abingdon, GBR, OX14 4SB
Physiomics PLC is a United Kingdom-based firm that provides consulting services to biopharmaceutical companies and research institutes in the areas of outsourced modelling and simulation (quantitative pharmacology), biometrics, and data science (bioinformatics). Its business activities involve the use of industry-standard technologies and a proprietary technology platform called Virtual Tumour. The company has three service lines: Biometrics, Modelling and Simulation (Quantitative Pharmacology) and Personalised Medicine. It derives revenue from the UK, the European Union and Switzerland.